

To: 5.1.2e [RDNBE] 5.1.2e @its.jnj.com]; 5.1.2e [JRDBE] 5.1.2e @its.jnj.com];
5.1.2e @imperial.nhs.uk]; 5.1.2e @imperial.nhs.uk]; 5.1.2e @gmail.com]; 5.1.2e @gmail.com];
5.1.2e @Novavax.com]; 5.1.2e @Novavax.com]; 5.1.2e @hotmail.es]; 5.1.2e @hotmail.es]; 5.1.2e
5.1.2e @umcutrecht.nl]; 5.1.2e @paediatrics.ox.ac.uk]; 5.1.2e @synapse-
managers.com]; 5.1.2e @synapse-managers.com]; 5.1.2e @medimmune.com]; 5.1.2e @medimmune.com];
5.1.2e @unipd.it]; 5.1.2e @unipd.it]; 5.1.2e @sergas.es]; 5.1.2e @sergas.es];
5.1.2e @biointelect.com]; 5.1.2e @biointelect.com]; 5.1.2e [JRDBE] 5.1.2e @its.jnj.com]; 5.1.2e @stx.ox.ac.uk];
5.1.2e @paediatrics.ox.ac.uk]; 5.1.2e @paediatrics.ox.ac.uk];
5.1.2e @imperial.ac.uk]; 5.1.2e @imperial.ac.uk]; 5.1.2e @gsk.com]; 5.1.2e @gsk.com];
5.1.2e @umcutrecht.nl]; 5.1.2e @umcutrecht.nl]; 5.1.2e @tcd.ie];
5.1.2e @Novavax.com]; 5.1.2e @Novavax.com]; 5.1.2e @umcutrecht.nl]; 5.1.2e @umcutrecht.nl];
5.1.2e @Novavax.com]; 5.1.2e @Novavax.com]; 5.1.2e @sanofipasteur.com]; 5.1.2e @sanofipasteur.com]; 5.1.2e
5.1.2e @paediatrics.ox.ac.uk]; 5.1.2e @unipd.it]; 5.1.2e @unipd.it]; 5.1.2e
5.1.2e @paediatrics.ox.ac.uk]; 5.1.2e @imperial.ac.uk]; 5.1.2e @imperial.ac.uk];
5.1.2e @pfizer.com]; 5.1.2e @pfizer.com]; 5.1.2e @imperial.ac.uk]; 5.1.2e @imperial.ac.uk];
5.1.2e @sanofi.com]; 5.1.2e @sanofi.com]; 5.1.2e [JRDNL] 5.1.2e @ITS.JNJ.com];
5.1.2e @sanofipasteur.com]; 5.1.2e @sanofipasteur.com]; 5.1.2e @paediatrics.ox.ac.uk];
5.1.2e @sanofi.com]; 5.1.2e @sanofi.com]; 5.1.2e
[JANNL] 5.1.2e @its.jnj.com]; 5.1.2e @sanofi.com]; 5.1.2e @sanofi.com];
5.1.2e @sanofi.com]; 5.1.2e @sanofi.com]; 5.1.2e @sanofi.com]; 5.1.2e @sanofi.com];
5.1.2e @GSK.COM]; 5.1.2e @GSK.COM]; 5.1.2e @nhs.net]; 5.1.2e @nhs.net];
5.1.2e @nhs.net]; 5.1.2e @nhs.net]; 5.1.2e @nhs.net]; 5.1.2e
5.1.2e @paediatrics.ox.ac.uk]; 5.1.2e @paediatrics.ox.ac.uk]; 5.1.2e [RDNBE Non-
J&J] 5.1.2e @its.jnj.com]; 5.1.2e @gsk.com]; 5.1.2e [JRDBE] 5.1.2e @its.jnj.com];
5.1.2e @GSK.COM]; 5.1.2e @GSK.COM]; 5.1.2e @GSK.COM];
5.1.2e @GSK.COM]; 5.1.2e @paediatrics.ox.ac.uk];
5.1.2e @umcutrecht.nl]; 5.1.2e @umcutrecht.nl]; 5.1.2e @rivm.nl]; 5.1.2e @ssi.dk]; 5.1.2e @ssi.dk];
5.1.2e @imperial.ac.uk]; 5.1.2e @imperial.ac.uk]; Rachel Anslow 5.1.2e @paediatrics.ox.ac.uk];
5.1.2e @gmail.com]; 5.1.2e @gmail.com]; 5.1.2e @gmail.com]; 5.1.2e @gmail.com];
Cc: 5.1.2e @paediatrics.ox.ac.uk]; 5.1.2e @umcutrecht.nl]; 5.1.2e @GSK.COM];
5.1.2e @medimmune.com]; 5.1.2e @GSK.COM]; 5.1.2e @astrazeneca.com]
5.1.2e [JRDBE] 5.1.2e @its.jnj.com]; 5.1.2e @astrazeneca.com]

From: 5.1.2e
Sent: Mon 3/9/2020 7:54:26 AM
Subject: RE: RESCEU WP5 Regular Skype Meeting
Received: Mon 3/9/2020 7:54:53 AM

Dear All

As discussed at the WP5 call last Friday please find below the age groups we need to fill for Group 2:

Age Group	Number Needed	Number Booked
<1month	5	0
2	4	0
4	4	0
5	2	0
6	4	0
9	3	2
11	1	0

Could recruiting sites please let me know when they have recruited into any of these groups and I will circulate an updated table?

Looking at the distribution of female versus male in Group 2, we have currently more male participants recruited into this group. I would therefore ask sites to recruit predominately females if this is at all possible.

Pease don't hesitate to contact me if there are any further questions.

Best wishes

5.1.2e

5.1.2e

Oxford Vaccine Group

Centre for Clinical Vaccinology and Tropical Medicine

Churchill Hospital

University of Oxford

Oxford OX3 7LE

Tel: 5.1.2e



5.1.2e

**From:** 5.1.2e [RDNBE] <5.1.2e@its.jnj.com>**Sent:** 03 February 2020 07:42

To: 5.1.2e [JRDBE] <5.1.2e@its.jnj.com>; 5.1.2e@imperial.nhs.uk; 5.1.2e@gmail.com;
 5.1.2e@Novavax.com; 5.1.2e@hotmail.es; 5.1.2e <5.1.2e@umcutrecht.nl>; 5.1.2e
 <5.1.2e@paediatrics.ox.ac.uk>; 5.1.2e@synapse-managers.com; 5.1.2e@medimmune.com;
 5.1.2e@unipd.it; 5.1.2e@sergas.es; 5.1.2e@biointellect.com; 5.1.2e [JRDBE]
 <5.1.2e@its.jnj.com>; 5.1.2e <5.1.2e@stx.ox.ac.uk>; 5.1.2e <5.1.2e@paediatrics.ox.ac.uk>; 5.1.2e
 5.1.2e <5.1.2e@paediatrics.ox.ac.uk>; 5.1.2e@imperial.ac.uk; 5.1.2e@gsk.com;
 5.1.2e@umcutrecht.nl; 5.1.2e <5.1.2e@tcd.ie>; 5.1.2e@Novavax.com; 5.1.2e@umcutrecht.nl;
 5.1.2e@Novavax.com; 5.1.2e@sanofipasteur.com; 5.1.2e <5.1.2e@paediatrics.ox.ac.uk>;
 5.1.2e@unipd.it; 5.1.2e <5.1.2e@paediatrics.ox.ac.uk>; 5.1.2e@imperial.ac.uk;
 5.1.2e@pfizer.com; 5.1.2e@imperial.ac.uk; 5.1.2e@sanofi.com; 5.1.2e [JRDNL]
 <5.1.2e@ITS.JNJ.com>; 5.1.2e@sanofipasteur.com 5.1.2e <5.1.2e@paediatrics.ox.ac.uk>;
 5.1.2e@sanofi.com; 5.1.2e [JANNL] <5.1.2e@its.jnj.com>;
 5.1.2e@sanofi.com; 5.1.2e@sanofi.com; 5.1.2e@sanofi.com; 5.1.2e@GSK.COM;
 5.1.2e@nhs.net; 5.1.2e@nhs.net; 5.1.2e@nhs.net; 5.1.2e <5.1.2e@paediatrics.ox.ac.uk>; 5.1.2e
 5.1.2e <5.1.2e@paediatrics.ox.ac.uk>; 5.1.2e [RDNBE Non-J&J] <5.1.2e@its.jnj.com>; 5.1.2e
 <5.1.2e@gsk.com>; 5.1.2e [JRDBE] <5.1.2e@its.jnj.com>; 5.1.2e@GSK.COM; 5.1.2e
 <5.1.2e@GSK.COM> (5.1.2e@GSK.COM) <5.1.2e@GSK.COM> 5.1.2e
 <5.1.2e@paediatrics.ox.ac.uk>; 5.1.2e <5.1.2e@paediatrics.ox.ac.uk>; 5.1.2e@umcutrecht.nl;
 5.1.2e@rivm.nl; 5.1.2e@ssi.dk; 5.1.2e@imperial.ac.uk 5.1.2e <5.1.2e@paediatrics.ox.ac.uk>;
 5.1.2e@gmail.com; 5.1.2e@gmail.com; 5.1.2e <5.1.2e@paediatrics.ox.ac.uk>
Cc: 5.1.2e <5.1.2e@paediatrics.ox.ac.uk>; 5.1.2e <5.1.2e@umcutrecht.nl>; 5.1.2e
 <5.1.2e@medimmune.com>; 5.1.2e <5.1.2e@GSK.COM>; 5.1.2e
 [JRDBE] <5.1.2e@its.jnj.com>; 5.1.2e <5.1.2e@astrazeneca.com>

Subject: RE: RESCEU WP5 Regular Skype Meeting

Dear all,

In the attachment you can see the minutes of the WP5 regular meetings which held on last Friday (31st of January).

Please let me know if you have any comments.

Kind regards,

5.1.2e 5.1.2e
5.1.2e Janssen Pharmaceutica
Infectious Diseases & Vaccines

Turnhoutseweg 30, Beerse 2340 (BE)
Building 5.1.2e
+32 5.1.2e

From: 5.1.2e [RDNBE]

Sent: Thursday, 30 January 2020 10:46

To: 5.1.2e [RDNBE] <5.1.2e @its.jnj.com>; 5.1.2e @imperial.nhs.uk' <5.1.2e @imperial.nhs.uk>;
5.1.2e @gmail.com' <5.1.2e @gmail.com>; 5.1.2e @Novavax.com' <5.1.2e @Novavax.com>;
5.1.2e @hotmail.es' <5.1.2e @hotmail.es>; 5.1.2e @umcutrecht.nl>;
5.1.2e @paediatrics.ox.ac.uk' <5.1.2e @paediatrics.ox.ac.uk>; 5.1.2e @synapse-managers.com'
<5.1.2e @synapse-managers.com>; 5.1.2e @medimmune.com' <5.1.2e @medimmune.com>; 5.1.2e @unipd.it'
<5.1.2e @unipd.it>; 5.1.2e @sergas.es' <5.1.2e @sergas.es>;
5.1.2e @biointellect.com' <5.1.2e @biointellect.com>; 5.1.2e [RDNBE] <5.1.2e @its.jnj.com>; 5.1.2e <5.1.2e
5.1.2e @stx.ox.ac.uk>; 5.1.2e <5.1.2e @paediatrics.ox.ac.uk>; 5.1.2e
<5.1.2e @paediatrics.ox.ac.uk>; 5.1.2e @imperial.ac.uk' <5.1.2e @imperial.ac.uk>;
5.1.2e @gsk.com' <5.1.2e @gsk.com>; 5.1.2e @umcutrecht.nl' <5.1.2e @umcutrecht.nl>;
5.1.2e <5.1.2e @tcd.ie>; 5.1.2e @Novavax.com' <5.1.2e @Novavax.com>; 5.1.2e @umcutrecht.nl'
<5.1.2e @umcutrecht.nl>; 5.1.2e @Novavax.com' <5.1.2e @Novavax.com>; 5.1.2e @sanofipasteur.com'
<5.1.2e @sanofipasteur.com>; 5.1.2e @paediatrics.ox.ac.uk' <5.1.2e @paediatrics.ox.ac.uk>;
5.1.2e @unipd.it' <5.1.2e @unipd.it>; 5.1.2e @paediatrics.ox.ac.uk'
<5.1.2e @paediatrics.ox.ac.uk>; 5.1.2e @imperial.ac.uk' <5.1.2e @imperial.ac.uk>;
5.1.2e @pfizer.com' <5.1.2e @pfizer.com>; 5.1.2e @imperial.ac.uk' <5.1.2e @imperial.ac.uk>;
5.1.2e @sanofi.com' <5.1.2e @sanofi.com>; 5.1.2e [RDNBE] <5.1.2e @ITS.JNJ.com>;
5.1.2e @sanofipasteur.com' <5.1.2e @sanofipasteur.com>; 5.1.2e @paediatrics.ox.ac.uk'
<5.1.2e @paediatrics.ox.ac.uk>; 5.1.2e @sanofi.com' <5.1.2e @sanofi.com>; 5.1.2e
5.1.2e [JANNL]' <5.1.2e @its.jnj.com>; 5.1.2e @sanofi.com' <5.1.2e @sanofi.com>;
5.1.2e @sanofi.com' <5.1.2e @sanofi.com>; 5.1.2e @sanofi.com' <5.1.2e @sanofi.com>;
5.1.2e @GSK.COM' <5.1.2e @GSK.COM>; 5.1.2e @nhs.net' <5.1.2e @nhs.net>; 5.1.2e @nhs.net'
<5.1.2e @nhs.net>; 5.1.2e @nhs.net' <5.1.2e @nhs.net>; 5.1.2e @paediatrics.ox.ac.uk'
<5.1.2e @paediatrics.ox.ac.uk>; 5.1.2e @paediatrics.ox.ac.uk' <5.1.2e @paediatrics.ox.ac.uk>; 5.1.2e
5.1.2e [RDNBE Non-J&J]' <5.1.2e @its.jnj.com>; 5.1.2e <5.1.2e @gsk.com>; 5.1.2e [RDNBE]'
<5.1.2e @its.jnj.com>; 5.1.2e @GSK.COM' <5.1.2e @GSK.COM>; 5.1.2e
<5.1.2e @GSK.COM> (5.1.2e @GSK.COM)' <5.1.2e @GSK.COM>;
5.1.2e @paediatrics.ox.ac.uk' <5.1.2e @paediatrics.ox.ac.uk>; 5.1.2e
<5.1.2e @paediatrics.ox.ac.uk>; 5.1.2e @umcutrecht.nl' <5.1.2e @umcutrecht.nl>; 5.1.2e @rivm.nl'
<5.1.2e @rivm.nl>; 5.1.2e @ssi.dk' <5.1.2e @ssi.dk>; 5.1.2e @imperial.ac.uk' <5.1.2e @imperial.ac.uk>;
5.1.2e @paediatrics.ox.ac.uk' <5.1.2e @paediatrics.ox.ac.uk>; 5.1.2e @gmail.com' <5.1.2e @gmail.com>;
5.1.2e @gmail.com' <5.1.2e @gmail.com>; 5.1.2e @paediatrics.ox.ac.uk>
Cc: 5.1.2e <5.1.2e @paediatrics.ox.ac.uk>; 5.1.2e <5.1.2e @umcutrecht.nl>; 5.1.2e
<5.1.2e @medimmune.com>; 5.1.2e <5.1.2e @GSK.COM>; 5.1.2e
[RDNBE]' <5.1.2e @its.jnj.com>; 5.1.2e <5.1.2e @astrazeneca.com>

Subject: RE: RESCEU WP5 Regular Skype Meeting


Dear all,

Please see the Skype call details and the agenda of the meeting below. The meeting will take place on Friday, 31st of January @ 3 pm CET.

Agenda

1. Case-control study progress


Overall numbers for season 1-3



Season 3 breakdown

Group 1	Seasons 1-3	Season 3 Only		
	Total	UMC	SERGAS	UK
Hosp (group 1a) Actual (target 250)	191	17	9	41
Not hosp (group 1b) Actual (target 250)	80	23	4	19
Co-morb hosp (group 1c) Actual (target 25)	29	1	2	3
Co-morb not hosp (group 1d) Actual (target 25)	1	0	0	0
Total	301	41	15	63

2. Case-control respiratory infections



3. Laboratory & biomarker assays update
 - a. Older adults – sample selection for CMI and systems serology assays
4. Birth cohort – assay prioritization for the samples with only one aliquot of serum
5. Other questions

Kind regards,

5.1.2e

[→ Join Skype Meeting](#)

Trouble Joining? [Try Skype Web App](#)

Join by phone

Toll number: 5.1.2i Digitale overleggen (Dial-in Number)

Dutch (Netherlands)

[Find a local number](#)

Conference ID: 1 2i Digitale overlegge
[Forgot your dial-in PIN?](#) | [Help](#)

HOW TO JOIN SKYPE MEETING AUDIO

1. "Use Skype for Business (full audio and video experience)" Select ONLY if you are using a USB connected Audio Device and have a good network connection (DO NOT SELECT THIS OPTION IF YOU ARE DIALING IN FROM A PHONE)
2. "Call Me at" Select if you have a phone that can be directly dialed (not supported in all countries).
3. "Don't join audio" Select if you will be dialing into the meeting from your phone.

Please note that J&J Skype for Business Meetings allow J&J meeting presenters to optionally record audio and other information shared during the meeting session, including any Instant Messages sent in the meeting. If a meeting presenter wishes to utilize the recording feature, the presenter should notify participants at the beginning of the meeting. Recorded participants will also be notified with either an audio or visual indication depending on how the participant is joined to the meeting. If you do not consent to being recorded, please discuss your concerns with the meeting organizer either prior to or at the beginning of the meeting, or do not join the meeting.
